Egorov A E
Vestn Oftalmol. 1996 Apr-Jun;112(2):3-4.
Effects of a carboanhydrase inhibitor 2% dorsolamine hydrochloride solution (Trusopt) on intraocular pressure and some ocular functions have been studied in patients with primary open-angle glaucoma (POAG): 10 patients aged 56 to 72 (16 eyes) with POAG and 5 patients aged 60 to 68 (8 eyes) with normal ophthalmic tone administered a single instillation of Trusopt and 15 subjects aged 63 to 82 (21 eyes) with POAG to whom Trusopt was administered three times daily for 14 days. A single instillation of the drug resulted in a reliable decrease of intraocular pressure both in glaucoma patients and subjects with normal ophthalmic tone. Maximal lowering of intraocular pressure was recorded 2 hours after instillation, by 21.4% of initial, on average. The hypotensive effect persisted for 12 hours (8.9% reduction of intraocular pressure). 80% of examinees complained of a sensation of short-term burning in the eye directly after instillation. Prolonged use of Trusopt was associated with a tendency to boosting the hypotensive effect: after 12 hours intraocular pressure was 15.4% lower than initially. Tonography showed a reliable (18.5%) reduction of aqueous humor production.
已对原发性开角型青光眼（POAG）患者研究了2%碳酸酐酶抑制剂盐酸多佐胺溶液（Trusopt）对眼压及一些眼功能的影响：10例年龄在56至72岁（16只眼）的POAG患者和5例年龄在60至68岁（8只眼）眼压正常的患者单滴入Trusopt；15例年龄在63至82岁（21只眼）的POAG患者每日三次滴入Trusopt，共14天。单滴入该药物使青光眼患者和眼压正常受试者的眼压均可靠降低。滴入后2小时记录到眼压最大降幅，平均为初始眼压的21.4%。降压作用持续12小时（眼压降低8.9%）。80%的受检者在滴入后立即抱怨眼睛有短期烧灼感。长期使用Trusopt有增强降压作用的趋势：12小时后眼压比初始眼压低15.4%。眼压描记显示房水生成可靠减少（18.5%）。
